Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

By J. McNamara, E. Andrechek, Yong Wang, Kristi D. Viles, R. Rempel, Eli Gilboa, B. Sullenger, P. Giangrande. Nature Biotechnology, 2006

991 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/97341f3b951dc752f1292c35d80f244ee85941ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Delivery of siRNA Therapeutics: Barriers and Carriers (2010, background): “... prostate-specifi cm embrane antigen (PSMA, a receptor overexpressed in prostate cancer cells) was internalized in PSMA-expressing cells, but not in PSMA-negative cells, and the repeated intratumoral injections of the A10-PLK1 chimera targeting the prosurvival gene PLK1 promoted tumor regression ”
Knocking down barriers: advances in siRNA delivery (2009, background): “It has therefore become a common approach to exploit the leaky vasculature of tumours for the purposes of directed delivery 7, 62, 63 .”
The delivery of therapeutic oligonucleotides (2016, background): “The chimera also had growth inhibitory effects when injected directly into the tumor (275).”
RNAi therapeutics: principles, prospects and challenges. (2007, background): “Other in vivo delivery approaches for siRNAs include conjugation of cholesterol to the siRNA sense strand [28], antibody-protamine fusions that bind siRNAs [29] cyclodextrin nanoparticles [30] and aptamer-siRNA conjugates [31].”
RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, methodology): “Very recently, aptamer-siRNA chimeric RNAs have also been used successfully to facilitate siRNA delivery in vivo, resulting in tumor regression in a xenograft model of prostate cancer 68 .”
Innovative approaches for cancer treatment: current perspectives and new challenges (2019, background): “A success is represented by siRNAs targeting PSMA, overexpressed in this type of cancer [204].”
Aptamers as therapeutics (2010, methodology): “Biotin-labelled aptamers were conjugated to biotin-labelled siRNAs via streptavidin 124 , or aptamers were hybridized to siRNAs 125 .”
RNA-based Therapeutics- Current Progress and Future Prospects (2012, background): “Also, aptamers can be combined with other types of therapeutic agents to serve as a delivery vehicle for siRNAs (McNamara et al., 2006; Neff et al., 2011; Pastor et al., 2010), enzymes (Chen et al., 2008), and anticancer drugs (Hicke et al., 2006; Hwang et al., 2010).”
Breaking down the barriers: siRNA delivery and endosome escape (2010, background): “…(Ab)-fusion molecules [Ab-protamine (Peer et al., 2007; Song et al., 2005) and Ab-poly-arginine (Kumar et al., 2008)], as well as cholesterol- (Soutschek et al., 2004; Zimmermann et al., 2006) and aptamer-conjugated siRNAs (Dassie et al., 2009; McNamara et al., 2006; Zhou et al., 2008) (Fig.”